In Case You Missed It
Before the Bell
Jim Cramer's Daily Booyah
Winners & Losers
Gilead (finally!) has acquired something from Sarepta, even if it is quite small.
TheStreet's Adam Feuerstein answers reader questions about biotech stocks.
TheStreet's Adam Feuerstein defends Sarepta Therapeutics
The Fed cannot move interest rates until fiscal policy is clear.
©1996-2017 TheStreet, Inc. All rights reserved.
Action Alerts PLUS is a registered trademark of TheStreet, Inc.